[Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology].

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Changes to anti-JCV antibody levels in a Swedish national MS cohort.Journal of neurology, neurosurgery, and psychiatry · 2013
   Article
2. Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.Journal of neural transmission (Vienna, Austria : 1996) · 2013
   Review
3. [Teriflunomide for treatment of multiple sclerosis].Der Nervenarzt · 2013
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

10 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as